Plasma Corin Levels Increased in Patients with Atrial Fibrillation
By LabMedica International staff writers Posted on 12 Jul 2015 |
Corin is a transmembrane protease, which is expressed primarily in cardiomyocytes, where it converts the inactive proatrial natriuretic peptide (proANP) and probrain natriuretic peptide (proBNP) into active peptides.
Enzyme-linked immunosorbent assays (ELISA) have been used to measure both corin and N-terminal proANP (NT-proANP) concentrations in plasma samples of patients with different manifestations of atrial fibrillation (AF) and suitable controls.
Cardiologists at the First Affiliated Hospital of Dalian Medical University (China) recruited a total of 268 subjects, including 141 AF patients; 83 with paroxysmal AF, 58 with persistent AF and 127 controls. Paroxysmal AF (PAF) was defined as AF episodes lasting less than seven days and which terminated spontaneously. Persistent AF (PeAF) was defined as AF episodes lasting more than seven days and/or requiring termination with pharmacologic or direct current cardioversion.
An ELISA kit (R&D Systems; Minneapolis, MN, USA) was used to measure corin concentrations in the study. After the reaction the optical density (OD) in the wells was recorded by a spectrometer microplate reader (BioTek; Winooski, VT, USA) with the absorbance wavelength at 450 nm and correction at 570 nm within 20 minutes. An ELISA kit (Biomedica; Vienna, Austria) was used to measure NT-proANP concentrations and the OD was measured within 20 minutes by the spectrometer at 450 nm.
Plasma corin concentrations in patients with AF and PeAF were 1,209 ± 510 pg/mL and 1,377 ± 548 pg/mL, respectively, which were significantly higher than those in controls at 973 ± 528 pg/mL. However, the difference between the PAF patients and controls was not statistically significant at 1,092 ± 448 pg/mL versus 973 ± 528 pg/mL. The difference between the two patient groups was significant, 1,092 ± 448 pg/mL versus 1,377 ± 548 pg/mL. The concentrations in male controls were significantly higher than that in the female controls 1,120 ± 577 pg/mL versus 713 ± 281 pg/mL, and in male patients, the plasma corin concentrations were also higher than that in female patients, 1,365 ± 485 pg/mL versus 842 ± 358 pg/mL.
The authors concluded that high plasma corin concentrations in patients with AF suggests that corin may play an important role in the pathology of AF and that plasma corin, like proANP and ANP, may be a useful biomarker for AF, although no correlation was found between plasma corin and NT-proANP concentrations both in controls and in cases. The study was published on July 20, 2015, in the journal Clinica Chimica Acta.
Related Links:
First Affiliated Hospital of Dalian Medical University
R&D Systems
BioTeck
Enzyme-linked immunosorbent assays (ELISA) have been used to measure both corin and N-terminal proANP (NT-proANP) concentrations in plasma samples of patients with different manifestations of atrial fibrillation (AF) and suitable controls.
Cardiologists at the First Affiliated Hospital of Dalian Medical University (China) recruited a total of 268 subjects, including 141 AF patients; 83 with paroxysmal AF, 58 with persistent AF and 127 controls. Paroxysmal AF (PAF) was defined as AF episodes lasting less than seven days and which terminated spontaneously. Persistent AF (PeAF) was defined as AF episodes lasting more than seven days and/or requiring termination with pharmacologic or direct current cardioversion.
An ELISA kit (R&D Systems; Minneapolis, MN, USA) was used to measure corin concentrations in the study. After the reaction the optical density (OD) in the wells was recorded by a spectrometer microplate reader (BioTek; Winooski, VT, USA) with the absorbance wavelength at 450 nm and correction at 570 nm within 20 minutes. An ELISA kit (Biomedica; Vienna, Austria) was used to measure NT-proANP concentrations and the OD was measured within 20 minutes by the spectrometer at 450 nm.
Plasma corin concentrations in patients with AF and PeAF were 1,209 ± 510 pg/mL and 1,377 ± 548 pg/mL, respectively, which were significantly higher than those in controls at 973 ± 528 pg/mL. However, the difference between the PAF patients and controls was not statistically significant at 1,092 ± 448 pg/mL versus 973 ± 528 pg/mL. The difference between the two patient groups was significant, 1,092 ± 448 pg/mL versus 1,377 ± 548 pg/mL. The concentrations in male controls were significantly higher than that in the female controls 1,120 ± 577 pg/mL versus 713 ± 281 pg/mL, and in male patients, the plasma corin concentrations were also higher than that in female patients, 1,365 ± 485 pg/mL versus 842 ± 358 pg/mL.
The authors concluded that high plasma corin concentrations in patients with AF suggests that corin may play an important role in the pathology of AF and that plasma corin, like proANP and ANP, may be a useful biomarker for AF, although no correlation was found between plasma corin and NT-proANP concentrations both in controls and in cases. The study was published on July 20, 2015, in the journal Clinica Chimica Acta.
Related Links:
First Affiliated Hospital of Dalian Medical University
R&D Systems
BioTeck
Read the full article by registering today, it's FREE!
Register now for FREE to LabMedica.com and get complete access to news and events that shape the world of Clinical Laboratory Medicine.
- Free digital version edition of LabMedica International sent by email on regular basis
- Free print version of LabMedica International magazine (available only outside USA and Canada).
- Free and unlimited access to back issues of LabMedica International in digital format
- Free LabMedica International Newsletter sent every week containing the latest news
- Free breaking news sent via email
- Free access to Events Calendar
- Free access to LinkXpress new product services
- REGISTRATION IS FREE AND EASY!
Sign in: Registered website members
Sign in: Registered magazine subscribers
Latest Clinical Chem. News
- 3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models
- POC Biomedical Test Spins Water Droplet Using Sound Waves for Cancer Detection
- Highly Reliable Cell-Based Assay Enables Accurate Diagnosis of Endocrine Diseases
- New Blood Testing Method Detects Potent Opioids in Under Three Minutes
- Wireless Hepatitis B Test Kit Completes Screening and Data Collection in One Step
- Pain-Free, Low-Cost, Sensitive, Radiation-Free Device Detects Breast Cancer in Urine
- Spit Test Detects Breast Cancer in Five Seconds
- Electrochemical Sensors with Next-Generation Coating Advances Precision Diagnostics at POC
- First-Of-Its-Kind Handheld Device Accurately Detects Fentanyl in Urine within Seconds
- New Fluorescent Sensor Array Lights up Alzheimer’s-Related Proteins for Earlier Detection
- Automated Mass Spectrometry-Based Clinical Analyzer Could Transform Lab Testing
- Highly Sensitive pH Sensor to Aid Detection of Cancers and Vector-Borne Viruses
- Non-Invasive Sensor Monitors Changes in Saliva Compositions to Rapidly Diagnose Diabetes
- Breakthrough Immunoassays to Aid in Risk Assessment of Preeclampsia
- Urine Test for Monitoring Changes in Kidney Health Markers Can Predict New-Onset Heart Failure
- AACC Releases Comprehensive Diabetes Testing Guidelines